
Johnson & Johnson Reports Landmark Phase 3 Study Results for gMG Treatment
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating nipocalimab, an investigational FcRn blocker, for generalized myasthenia gravis (gMG). …
Johnson & Johnson Reports Landmark Phase 3 Study Results for gMG Treatment Read More